-0.000454270139309527 -0.00121138703815867 -0.00423985463355544 -0.0071168988491823 -0.0069654754694126 -0.0104482132041187 -0.0131738340399758 -0.0131738340399758
Sign Up Today X
Thanks for submitting the form.
Stockreport

Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets [Yahoo! Finance]

Incyte Corporation (INCY)  More Company Research Source: Yahoo! Finance
Last incyte corporation earnings: 2/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: incyte.com/ir/investor-overview.aspx
In second quarter 2024, the drug generated sales of $705.9 million, +3% year-over-year, driven by a 9% increase in paid demand The analyst downgraded the stock from Buy to Hold, with a price target of $74, down from $83 With Jakafi's loss of exclusivity approaching, a key concern is whether Incyte's pipeline in immunology, inflammation (I&I), and oncology can compensate for the revenue decline expected from generic competition. While there is long-term growth potential in the company's pipeline—supported by strong Phase 2 data and opportunities for expansion into new indications or combination therapies—the challenge of mitigating the patent cliff remains significant. Additionally, Incyte faces intense competition, particularly in larger markets where it aims to establish a foothold, such as I&I and solid tumors. Truist emphasizes the significance of the late-stage results for Povorcitinib in hidradenitis suppurativa (HS), expected in the first half of 2025, as a key factor l [Read more]
IMPACT SNAPSHOT EVENT TIME: INCY
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
INCY alerts
from News Quantified
INCY
NEWS
INCY
Earnings
INCY
Analyst Actions
INCY
SEC Filings
Stockreport

Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets [Yahoo! Finance]

Incyte Corporation  (INCY) 
More Company Research Source: Yahoo! Finance
Last incyte corporation earnings: 2/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: incyte.com/ir/investor-overview.aspx
In second quarter 2024, the drug generated sales of $705.9 million, +3% year-over-year, driven by a 9% increase in paid demand The analyst downgraded the stock from Buy to Hold, with a price target of $74, down from $83 With Jakafi's loss of exclusivity approaching, a key concern is whether Incyte's pipeline in immunology, inflammation (I&I), and oncology can compensate for the revenue decline expected from generic competition. While there is long-term growth potential in the company's pipeline—supported by strong Phase 2 data and opportunities for expansion into new indications or combination therapies—the challenge of mitigating the patent cliff remains significant. Additionally, Incyte faces intense competition, particularly in larger markets where it aims to establish a foothold, such as I&I and solid tumors. Truist emphasizes the significance of the late-stage results for Povorcitinib in hidradenitis suppurativa (HS), expected in the first half of 2025, as a key factor l [Read more]
IMPACT SNAPSHOT
EVENT TIME:
INCY
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS